Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Jay Y Spiegel¹, Saurabh Dahiya², Michael D Jain³, John Tamaresis¹, Loretta J Nastoupil⁴, Miriam T Jacobs⁵, Armin Ghobadi⁵, Yi Lin⁶, Matthew Lunning⁷, Lazaros Lekakis⁸, Patrick Reagan⁹, Olalekan Oluwole¹⁰, Joseph McGuirk¹¹, Abhinav Deol¹², Andre Goy¹³, Khoan Vu¹⁴, Charalambos Andreadis¹⁴, Javier Munoz¹⁵, N Nora Bennani⁶, Julie M Vose⁷, Kathleen A Dorritie¹⁶, Sattva S Neelapu⁴, Frederick L Locke³, Aaron P Rapoport², Brian T Hill¹⁷, David B Miklos¹

Affiliations

¹ Stanford University Medical Center, Stanford, CA.
² University of Maryland School of Medicine-Greenebaum Comprehensive Cancer Center, Baltimore, MD.
³ Moffitt Cancer Center, Tampa, FL.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
⁶ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
⁷ University of Nebraska Medical Center, Omaha, NE.
⁸ University of Miami Miller School of Medicine, Miami, FL.
⁹ University of Rochester Medical Center, Rochester, NY.
¹⁰ Vanderbilt-Ingram Cancer Center, Nashville, TN.
¹¹ University of Kansas Medical Center, Kansas City, KS.
¹² Karmanos Center Institute/Wayne State University, Detroit, MI.
¹³ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ.
¹⁴ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA.
¹⁵ Banner MD Anderson Cancer Center, Gilbert, AZ.
¹⁶ UPMC Hillman Cancer Center, Pittsburgh, PA; and.
¹⁷ Division of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

PMID: 33156925
PMCID: PMC8555382
DOI: 10.1182/blood.2020006245

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Jay Y Spiegel et al. Blood. 2021.

. 2021 Apr 1;137(13):1832-1835.

doi: 10.1182/blood.2020006245.

Authors

Affiliations

¹ Stanford University Medical Center, Stanford, CA.
² University of Maryland School of Medicine-Greenebaum Comprehensive Cancer Center, Baltimore, MD.
³ Moffitt Cancer Center, Tampa, FL.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
⁶ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
⁷ University of Nebraska Medical Center, Omaha, NE.
⁸ University of Miami Miller School of Medicine, Miami, FL.
⁹ University of Rochester Medical Center, Rochester, NY.
¹⁰ Vanderbilt-Ingram Cancer Center, Nashville, TN.
¹¹ University of Kansas Medical Center, Kansas City, KS.
¹² Karmanos Center Institute/Wayne State University, Detroit, MI.
¹³ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ.
¹⁴ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA.
¹⁵ Banner MD Anderson Cancer Center, Gilbert, AZ.
¹⁶ UPMC Hillman Cancer Center, Pittsburgh, PA; and.
¹⁷ Division of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

PMID: 33156925
PMCID: PMC8555382
DOI: 10.1182/blood.2020006245

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
**Factors affecting survival after axi-cel progression.** (A) Unstratified Kaplan-Meier analysis of OS after axi-cel progression. (B-D) OS stratified according to cytokine release syndrome (CRS), bridging therapy and response to axi-cel. Gr, grade; SD, stable disease.

See this image and copyright information in PMC

Cited by

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
Zhang W, Huang C, Liu R, Zhang H, Li W, Yin S, Wang L, Liu W, Liu L. Zhang W, et al. Front Immunol. 2022 Oct 5;13:983934. doi: 10.3389/fimmu.2022.983934. eCollection 2022. Front Immunol. 2022. PMID: 36275715 Free PMC article.
Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy.
Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN. Furqan F, et al. Blood Adv. 2023 Jun 13;7(11):2463-2467. doi: 10.1182/bloodadvances.2022009025. Blood Adv. 2023. PMID: 36417762 Free PMC article. No abstract available.
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, Pabst T. Rentsch V, et al. Cancers (Basel). 2022 May 20;14(10):2516. doi: 10.3390/cancers14102516. Cancers (Basel). 2022. PMID: 35626120 Free PMC article.
Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N, Smith M. Jeyakumar N, et al. Front Immunol. 2022 May 18;13:887866. doi: 10.3389/fimmu.2022.887866. eCollection 2022. Front Immunol. 2022. PMID: 35663947 Free PMC article. Review.
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes.
Jain MD, Spiegel JY. Jain MD, et al. EJHaem. 2021 Dec 8;3(Suppl 1):46-53. doi: 10.1002/jha2.357. eCollection 2022 Jan. EJHaem. 2021. PMID: 35844298 Free PMC article. Review.

See all "Cited by" articles

References

1. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. - PMC - PubMed
1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. - PMC - PubMed
1. Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019;94(8):E209-E213. - PMC - PubMed
1. Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(11):e344-e351. - PMC - PubMed
1. Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]. Blood. 2019;134(suppl 1). Abstract 764.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Affiliations

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources